Megestrol acetate in cancer patients with anorexia-cachexia syndrome: A meta-analysis

Translational Cancer Research

Volumn 2, Issue 2, 2013, Pages 74-79

  Zhan, Ping ^a   Wang, Qin ^b   Qian, Qian ^a   Yu, Li Ke ^a  

^a NANJING CHEST HOSPITAL   (China)

^b 81 Hospital of PLA   (China)

Author keywords

Anorexia cachexia syndrome (ACS); Cancer patients; Megestrol acetate (MA); Meta analysis; Randomized controlled trials (RCT)

Indexed keywords

MEGESTROL ACETATE;

ANOREXIA; ARTICLE; CACHEXIA; CANCER PATIENT; CANCER RISK; HUMAN; INCREASED APPETITE; MEDLINE; META ANALYSIS; ONCOLOGY; SYSTEMATIC REVIEW; WEB OF SCIENCE; WEIGHT GAIN;

EID: 84962755792     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2013.04.13     Document Type: Article

References (31)

1. Nelson KA, Walsh D, Hussein M. A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer. Am J Hosp Palliat Care 2002;19:206-10.
2. Splinter TA. Cachexia and cancer: a clinician's view. Ann Oncol 1992;3 Suppl 3:25-7.
3. Argilés JM, Meijsing SH, Pallarés-Trujillo J, et al. Cancer cachexia: a therapeutic approach. Med Res Rev 2001;21:83-101.
4. Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology (Williston Park) 1996;10:1049-56; discussion 1062-4, 1067-8.
5. Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49 Suppl 2:35-42.
6. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
7. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: the nordic cochrane centre, the cochrane collaboration, 2008.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
11. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
12. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.
13. Tchekmedyian NS, Hickman M, Siau J, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74.
14. Feliu J, González-Barón M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. Am J Clin Oncol 1992;15:436-40.
15. Schmoll E. Risks and benefits of various therapies for cancer anorexia. Oncology 1992; 49 Suppl 2:43-5.
16. Lai YL, Fang FM, Yeh CY. Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone. J Pain Symptom Manage 1994;9:265-8.
17. McMillan DC, Simpson JM, Preston T, et al. Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clin Nutr 1994;13:85-9.
18. Zecca E, Martini C, Venturino P, et al. Efficacy of megestrol acetate on anorexia in patients with advanced non hormone-related tumors: a double-blind placebo controlled clinical trial. Eur J Cancer 1995;31:S261-S262.
19. Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996;14:135-41.
20. Fietkau R, Riepl M, Kettner H, et al. Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer 1997;33:75-9.
21. Vadell C, Seguí MA, Giménez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998;21:347-51.
22. Erkurt E, Erkisi M, Tunali C. Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. J Exp Clin Cancer Res 2000;19:431-9.
23. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95.
24. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410.
25. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
26. Pascual López A, Roqué i Figuls M, Umjtia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syn-drome. J Pain Symptom Manage 2004;27:360-9.
27. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treat-ment of cancer anorexia-cachexia syndrome: a systematic review of ran-domized clinical trials. Ann Oncol 2001;12:289-300.
28. Berenstein EG, Ortiz Z. Megestrol acetate for treatment of anorexia-cacbexia syndrome. Cochrane Database Syst Rev 2005;(2):CD004310.
29. Balog DL, Epstein ME, Amodio-Groton MI. HIV wasting syndrome: treatment update. Ann Pharmacother 1998;32:446-58.
30. Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-6.
31. Wigmore SJ, Fearon KC, Maingay JP, et al. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 1997;92:215-21.